MCID: SRS001
MIFTS: 57

Serous Cystadenocarcinoma malady

Cancer diseases category

Summaries for Serous Cystadenocarcinoma

About this section
Sources:
8Disease Ontology, 63Wikipedia, 32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Disease Ontology:8 A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue forming serous lesions.

MalaCards: Serous Cystadenocarcinoma, also known as serous cystadenocarcinoma, nos, is related to cystadenocarcinoma and adenocarcinoma. An important gene associated with Serous Cystadenocarcinoma is ESR2 (estrogen receptor 2 (ER beta)), and among its related pathways are IL-3 Signaling Pathway and TNF Signaling. The compounds resveratrol and idoxifene have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and testis, and related mouse phenotypes are hearing/vestibular/ear and integument.

Wikipedia:63 Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. more...

Aliases & Classifications for Serous Cystadenocarcinoma

About this section
Sources:
8Disease Ontology, 10DISEASES, 44Novoseek, 60UMLS, 34MeSH, 56SNOMED-CT, 39NCIt
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


Aliases & Descriptions:

serous cystadenocarcinoma 8 10
serous cystadenocarcinoma, nos 8
cystadenocarcinoma, serous 60
cystadenocarcinoma serous 44
serous adenocarcinoma 8
serous carcinoma 8


External Ids:

Disease Ontology8 DOID:3114
MeSH34 D018284
SNOMED-CT56 189685001, 90725004

Related Diseases for Serous Cystadenocarcinoma

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 195)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma31.6MUC16
2adenocarcinoma31.3BAX, VEGFA, AKT1, FAS, MUC16, PGR
3ovarian serous cystadenocarcinoma31.2ZNF217, MUC16, USP2, USP14, UBE4A
4papillary carcinoma31.2ESR1, PGR, MUC16
5endometrial carcinoma30.8BCL2, ESR2, ESR1, PGR, MUC16
6peritonitis30.5MUC16
7ovarian cancer30.3FAS, AKT1, VEGFA, BAX, MUC16, CYP19A1
8breast cancer30.2FAS, AKT1, VEGFA, BAX, MUC16, CYP19A1
9adenofibroma30.1MUC16
10leiomyosarcoma30.1PGR, MUC16
11endometriosis30.1VEGFA, MUC16, CYP19A1, PGR, ESR1, ESR2
12leukemia30.1FAS, AKT1, BAX, BIRC5, ESR2, BCL2
13malignant mesothelioma30.0MUC16
14astrocytoma30.0VEGFA, AKT1
15gastric adenocarcinoma30.0FAS, BAX, MUC16, BIRC5, BCL2
16lung adenocarcinoma30.0FAS, VEGFA, BAX, MUC16, BIRC5, ESR2
17rhabdomyosarcoma29.9AKT1
18tuberous sclerosis29.9AKT1
19ovarian disease29.9MUC16, CYP19A1
20lymphangioleiomyomatosis29.9ESR1, PGR
21leiomyoma29.9CYP19A1, PGR, ESR1, ESR2
22melanoma29.9FAS, AKT1, VEGFA, BAX, BIRC5, BCL2
23papillary cystadenocarcinoma10.8
24ovarian cystadenocarcinoma10.8
25papillary adenocarcinoma10.7
26ovary serous adenocarcinoma10.5
27pancreatic serous cystadenocarcinoma10.5
28ovary adenocarcinoma10.5
29peritoneal serous adenocarcinoma10.5
30fallopian tube serous adenocarcinoma10.4
31pancreatic cystadenocarcinoma10.4
32pancreatitis10.4
33ovarian malignant mesothelioma10.3
34ovary papillary carcinoma10.3
35cervical serous adenocarcinoma10.2
36uterine ligament serous adenocarcinoma10.2
37peritoneal serous papillary adenocarcinoma10.2
38fallopian tube adenocarcinoma10.2
39hepatitis10.2
40malignant peritoneal mesothelioma10.2
41in situ carcinoma10.2
42uterine corpus serous adenocarcinoma10.2
43breast adenocarcinoma10.2
44endometrial adenocarcinoma10.2
45endocervical carcinoma10.1
46neuroendocrine carcinoma10.1
47endocervicitis10.1
48large cell carcinoma10.1
49transitional cell carcinoma10.1
50uterine disease10.1

Graphical network of the top 20 diseases related to Serous Cystadenocarcinoma:



Diseases related to serous cystadenocarcinoma

Clinical Features for Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Serous Cystadenocarcinoma

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials, 60UMLS, 40NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Serous Cystadenocarcinoma

Drug clinical trials:

Search ClinicalTrials for Serous Cystadenocarcinoma

Search NIH Clinical Center for Serous Cystadenocarcinoma

Search CenterWatch for Serous Cystadenocarcinoma

Genetic Tests for Serous Cystadenocarcinoma

About this section

Anatomical Context for Serous Cystadenocarcinoma

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Serous Cystadenocarcinoma:

32
Ovary, Pancreas, Testis, Colon, Breast, Bone, Liver, Spleen, Lymph node, Testes

Animal Models for Serous Cystadenocarcinoma or affiliated genes

About this section
Sources:
36MGI
See all sources

Publications for Serous Cystadenocarcinoma

About this section
Sources:
50PubMed
See all sources

Articles related to Serous Cystadenocarcinoma:

(show top 50)    (show all 100)
idTitleAuthorsYear
1
Serous papillary cystadenocarcinoma in supernumerary ovary. (23550880)
2013
2
Peritoneal papillary serous cystadenocarcinoma at a previous laparoscopic trocar site. (23040941)
2012
3
Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen. (22066125)
2011
4
Serous papillary cystadenocarcinoma arising from autografted ovary of the abdominal wall. (19147508)
2010
5
Serous cystadenocarcinoma of the pancreas with portal thrombosis. (20499029)
2010
6
Papillary serous cystadenocarcinoma of the stomach, peritoneum and ovary. (20163045)
2009
7
Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. (18818939)
2009
8
Serous cystadenocarcinoma of the ovary in an 11-year-old girl with extensive dissemination and chylothorax: a case report and a brief review of literature. (19564753)
2009
9
Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst. (19317271)
2009
10
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
11
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
12
Primary papillary serous cystadenocarcinoma of broad ligament. (15845057)
2005
13
Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. (16012716)
2005
14
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. (15032078)
2004
15
A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. (14551796)
2004
16
Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. (15025299)
2003
17
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
18
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. (12574850)
2001
19
Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. (10886734)
2000
20
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. (10968352)
2000
21
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
22
Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary. (9642449)
1998
23
Case report: Serous cystadenocarcinoma of the retroperitoneum: CT and sonographic appearance. (9867279)
1998
24
Ovarian serous papillary cystadenocarcinoma stage IIIC in a 19-year-old. (9038277)
1997
25
Morphologic criteria for the prognosis of serous cystadenocarcinoma of the ovary. (7737584)
1995
26
Colonic carcinoma metastasis to ovary having serous cystadenocarcinoma -- an unusual case of double ovarian malignancy. (8932579)
1995
27
Lymphadenectomy in stage-III serous cystadenocarcinoma of the ovary. (8745090)
1995
28
Stage III papillary serous cystadenocarcinoma of the ovary in a 15-year-old female. (8188094)
1994
29
Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. (9205465)
1994
30
Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. (8424699)
1993
31
Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary. (8482567)
1993
32
An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. (1506732)
1992
33
Successful pregnancy after conservative surgery for ovarian papillary serous cystadenocarcinoma of low malignant potential. (1785199)
1991
34
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
35
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (2482644)
1989
36
Serous cystadenocarcinoma of the pancreas: a new entity? (2909198)
1989
37
Parovarian serous cystadenocarcinoma of borderline malignancy diagnosed during pregnancy. (3240895)
1988
38
Primary tumor of the rectovaginal septum: mesothelioma or papillary serous cystadenocarcinoma. A case report with transmission electron microscopy. (3668422)
1987
39
Serous cystadenocarcinoma as incidental finding during a repeat cesarean section. (4037003)
1985
40
Serous papillary cystadenocarcinoma associated with alpha-fetoprotein production. (6205636)
1984
41
Hyperamylasemia with papillary serous cystadenocarcinoma of the ovary. (6206939)
1984
42
Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. (6583437)
1984
43
Mixed Mullerian tumour of ovary in association with breast carcinoma and serous cystadenocarcinoma carcinoma of other ovary. (6273302)
1981
44
Paramesonephric papillary serous cystadenocarcinoma: a case report with scanning electron microscopy. (6942626)
1981
45
Classification and survival rate of patients with serous cystadenocarcinoma of the ovaries. (1004656)
1976
46
Benign papillary peritoneal cystosis simulating serous cystadenocarcinoma of the ovary. (4812581)
1974
47
An immunologic comparison between serous cystadenocarcinoma of the ovary and other human gynecologic tumors. (4126800)
1973
48
Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. (4910128)
1970
49
COEXISTENT BILATERAL PAPILLARY SEROUS CYSTADENOCARCINOMA AND BILATERAL BENIGN CYSTIC TERATOMA IN PREGNANCY. REPORT OF A CASE. (14211024)
1964
50
Serous cystadenocarcinoma of ovary, bilateral, stage II, six-year survival. A case report. (13981334)
1963

Genetic Variations for Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Serous Cystadenocarcinoma.

Pathways for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
37NCBI BioSystems Database, 55SinoBiological, 52R&D Systems, 53Reactome, 51QIAGEN, 49PharmGKB, 12EMD Millipore, 29KEGG, 4Cell Signaling Technology
See all sources

Pathways related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 31)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.3BIRC5
2
Hide members
10.3AKT1
310.0ESR2, PGR, CYP19A1
49.9BCL2, BIRC5, AKT1
59.9ESR2, ESR1, AKT1
69.9ESR2, ESR1, AKT1
7
Hide members
9.9ESR2, ESR1, PGR
89.9BCL2, BAX, AKT1
9
Hide members
9.9AKT1, BAX, BCL2
10
Hide members
9.9AKT1, BAX, BCL2
119.9AKT1, BAX, BCL2
12
Hide members
9.9ESR2, ESR1, CYP19A1
139.9BCL2, BAX, FAS
149.9BCL2, ESR1, AKT1
15
Hide members
9.8BCL2, BIRC5, BAX, AKT1
169.7FAS, BAX, BIRC5, BCL2
17
Apoptosis and survival Apoptotic TNF-family pathways
Hide members
9.7BCL2, BIRC5, BAX, FAS
18
Apoptosis and survival Caspase cascade
Hide members
9.7FAS, AKT1, BAX, BCL2
19
Hide members
9.7FAS, AKT1, BAX, BCL2
20
Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2
Hide members
9.7BAX, ESR1, ESR2, BCL2
21
Development Endothelin-1/EDNRA signaling
Hide members
9.7AKT1, VEGFA, ESR1, ESR2
229.7ESR1, VEGFA, AKT1, FAS
23
Hide members
9.6FAS, AKT1, BAX, BIRC5, BCL2
24
Hide members
9.6FAS, AKT1, BAX, BIRC5, BCL2
25
Development Prolactin receptor signaling
Hide members
9.6AKT1, BAX, ESR1, ESR2, BCL2
269.4AKT1, AMY1A, AMY1B, AMY1C
27
Hide members
9.4AMY1C, AMY1B, AMY1A, CYP19A1
289.4FAS, AKT1, VEGFA, BAX, BIRC5, BCL2
29
Hide members
9.3FAS, AKT1, VEGFA, BAX, ESR1, BCL2
309.3AKT1, VEGFA, BAX, CYP19A1, ESR1, BCL2
319.2BCL2, FAS, AKT1, VEGFA, BAX, ESR1

Compounds for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
44Novoseek, 59Tocris Bioscience, 11DrugBank, 24HMDB, 49PharmGKB, 28IUPHAR, 2BitterDB
See all sources

Compounds related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 195)
idCompoundScoreTop Affiliating Genes
1resveratrol44 59 11 2413.7PGR
2idoxifene4410.2CYP19A1, ESR1, PGR
3ponicidin4410.2BAX, BIRC5, BCL2
4estradiol benzoate4410.1PGR, ESR1, CYP19A1, ESR2
5nandrolone44 2411.1CYP19A1, PGR, ESR1, ESR2
6leuprolide acetate4410.1CYP19A1, PGR, ESR1, ESR2
7exemestane49 44 59 1113.1ESR1, PGR, CYP19A1, ESR2
8bisphenol a4410.1CYP19A1, PGR, ESR1, ESR2
9tanshinone iia4410.1FAS, BCL2, BAX
10lapatinib44 49 1112.1BIRC5, ESR1, PGR, CYP19A1
113,3-diindolylmethane4410.1VEGFA, BIRC5, ESR1, BAX
12clomiphene citrate4410.1PGR, ESR1, CYP19A1, ESR2
13hoechst 333424410.0FAS, BIRC5, BAX, BCL2
14fulvestrant44 49 28 1113.0PGR, ESR1, ESR2, CYP19A1
155fluorouracil4410.0FAS, BAX, PGR, BCL2, BIRC5
16letrozole44 49 59 1113.0CYP19A1, PGR, ESR2, ESR1
17toremifene44 1111.0CYP19A1, PGR, ESR1, ESR2, FAS
18levonorgestrel44 59 28 1113.0ESR2, ESR1, CYP19A1, PGR
194-hydroxytamoxifen449.9CYP19A1, ESR1, PGR, AKT1, ESR2
20noxa449.9BIRC5, BCL2, BAX, FAS
21indole-3-carbinol449.8BAX, AKT1, CYP19A1, BIRC5, ESR1, BCL2
22adriamycin449.8BIRC5, BCL2, PGR, BAX, AKT1, FAS
23gefitinib44 49 1111.8ESR1, CYP19A1, VEGFA, AKT1, BIRC5, ESR2
24celecoxib44 59 28 49 11 2414.8VEGFA, BAX, AKT1, CYP19A1, BCL2, BIRC5
25progestin449.8VEGFA, ESR1, PGR, CYP19A1, ESR2
26thymidylate449.8BIRC5, BAX, VEGFA, ESR2, FAS, BCL2
27taxane449.8VEGFA, CYP19A1, PGR, BIRC5, BCL2, ESR1
28gemcitabine44 49 1111.7BCL2, CYP19A1, BAX, VEGFA, AKT1, BIRC5
29trastuzumab44 49 1111.7BIRC5, ESR1, CYP19A1, VEGFA, PGR, FAS
30steroidal449.7ESR2, CYP19A1, ESR1, PGR
31etoposide44 49 59 1112.7BAX, ESR2, AKT1, FAS, BCL2
32dexamethasone44 49 28 1112.7FAS, BCL2, BIRC5, MUC16, VEGFA, AKT1
332-chlorodeoxyadenosine449.6FAS, BAX, BIRC5, BCL2
34mifepristone44 59 28 1112.6VEGFA, BAX, CYP19A1, PGR, BIRC5, ESR2
35arsenite44 2410.6FAS, VEGFA, BAX, AKT1, BCL2, BIRC5
36mg 13244 5910.6BIRC5, AKT1, ESR1, VEGFA, BAX, FAS
37docetaxel44 49 59 1112.6CYP19A1, PGR, BIRC5, VEGFA, BAX, BCL2
38ly294002449.5ESR1, BAX, VEGFA, AKT1, FAS, BIRC5
39actinomycin d449.4BCL2, ESR1, BIRC5, BAX, VEGFA, AKT1
40sb 20358044 5910.4BCL2, BAX, BIRC5, FAS, VEGFA, AKT1
41testosterone44 59 11 2412.3ESR2, AKT1, MUC16, CYP19A1, PGR, BIRC5
42cisplatin44 49 59 1112.2BCL2, BIRC5, MUC16, BAX, VEGFA, AKT1
43tamoxifen44 49 28 1112.1BCL2, ESR2, FAS, AKT1, VEGFA, CYP19A1
44genistein44 28 59 2 11 2414.1ESR2, BCL2, FAS, AKT1, VEGFA, BAX
45n acetylcysteine449.1BCL2, BIRC5, BAX, AKT1, FAS, VEGFA
46retinoic acid44 2410.0BIRC5, FAS, ESR2, AKT1, ESR1, PGR
47paraffin449.0AKT1, FAS, BAX, MUC16, PGR, VEGFA
48vegf449.0FAS, BCL2, ESR2, ESR1, BIRC5, PGR
49paclitaxel44 49 1111.0MUC16, FAS, BIRC5, BCL2, AKT1, BAX
50doxorubicin44 49 1110.8BCL2, VEGFA, PGR, ESR1, FAS, CYP19A1

GO Terms for genes affiliated with Serous Cystadenocarcinoma

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:04693010.1BCL2, BAX

Biological processes related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1regulation of nitrogen utilizationGO:00680810.4BAX, BCL2
2renal system processGO:00301410.4BCL2, FAS
3activation-induced cell death of T cellsGO:00692410.4AKT1, FAS
4regulation of protein heterodimerization activityGO:04349710.3BAX, BCL2
5regulation of protein homodimerization activityGO:04349610.3BAX, BCL2
6transformed cell apoptotic processGO:00692710.3FAS, BAX
7vagina developmentGO:06006810.3ESR2, ESR1, BAX
8neuron apoptotic processGO:05140210.2BCL2, BAX, FAS
9intrinsic apoptotic signaling pathwayGO:09719310.2BCL2, BAX, AKT1
10uterus developmentGO:06006510.2ESR1, ESR2
11positive regulation of peptidyl-serine phosphorylationGO:03313810.2AKT1, VEGFA, BCL2
12negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.2AKT1, VEGFA, BIRC5
13positive regulation of nitric-oxide synthase activityGO:05100010.1ESR1, AKT1
14response to toxic substanceGO:00963610.1BCL2, BAX, FAS
15ovarian follicle developmentGO:00154110.0BCL2, ESR2, BAX, VEGFA
16positive regulation of sequence-specific DNA binding transcription factor activityGO:0510919.9ESR2, ESR1, AKT1
17response to acidGO:0011019.8BCL2, BAX
18positive regulation of apoptotic processGO:0430659.7FAS, AKT1, BAX, ESR2
19negative regulation of apoptotic processGO:0430669.7FAS, AKT1, VEGFA, BIRC5, BCL2

Molecular functions related to Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.3ESR2, ESR1
2BH3 domain bindingGO:05143410.2BCL2, BAX
3steroid bindingGO:00549610.1PGR, ESR1, ESR2
4estrogen receptor activityGO:03028410.1ESR1, ESR2
5core promoter sequence-specific DNA bindingGO:00104610.1ESR2, ESR1
6steroid hormone receptor activityGO:00370710.0ESR2, ESR1, PGR
7nitric-oxide synthase regulator activityGO:03023510.0ESR1, AKT1
8enzyme bindingGO:0198999.8ESR2, ESR1, BIRC5, PGR, AKT1
9channel activityGO:0152679.8BCL2, BAX
10identical protein bindingGO:0428029.1BCL2, FAS, USP2, AKT1, VEGFA, BAX
11protein bindingGO:0055157.0VEGFA, AKT1, USP2, USP14, FAS, UBE4A

Products for genes affiliated with Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Serous Cystadenocarcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet